Eli Lilly has entered into a $100 million licensing agreement with CSL Ltd. for clazakizumab, a monoclonal antibody designed to target interleukin-6 (IL-6). The strategic move allows the Indianapolis-based pharmaceutical giant to bolster its immunology and anti-inflammatory pipeline following a year of record growth in its metabolic health franchise.
Key aspects of the partnership include:
-
Retained Rights: CSL will continue to spearhead the Phase 3 clinical trials for clazakizumab specifically for preventing cardiovascular complications in patients with end-stage kidney disease.
-
Expansion: Eli Lilly is granted the rights to explore and commercialize the drug for a variety of other therapeutic indications.
-
Financials: Beyond the $100 million upfront fee, CSL is eligible for further milestone payments tied to regulatory approvals and commercial success, alongside tiered royalties on global sales.
The drug aims to mitigate chronic inflammation by neutralizing the IL-6 cytokine. While a previous trial focused on organ transplant rejection was discontinued due to low efficacy, IL-6 remains a high-value target in the industry, as evidenced by the success of existing therapies for rheumatoid arthritis and other inflammatory disorders. This deal marks Lilly’s continued aggressive expansion into the immunology sector, following several multi-billion dollar acquisitions earlier this year.